The Japanese Journal of Dermatology
Online ISSN : 1346-8146
Print ISSN : 0021-499X
ISSN-L : 0021-499X
Original Articles
Management of Cyclosporine Therapy Based on the TDM (therapeutic Drug Monitoring) for Psoriasis
Yoshinori UmezawaMika KonnoTomotakai MabuchiMariko IizukaTakashi MatsuyamaYo KawakuboAkira Ozawa
Author information
Keywords: cyclosporine, psoriasis, TDM, AUC

2002 Volume 112 Issue 10 Pages 1367-1370


The clinical efficacy of cyclosporine (CYA) therapy for psoriasis has been established. However, side effects associated with toxicity of CYA have been also discussed. It may be important to determine CYA dosage based on the TDM for psoriasis, in order to have more therapeutic success without adverse events. In this study, we investigated the possibility of using the TDM as a therapeutic marker for psoriasis treatment with CYA-MEPC (Neoral). Twenty-two patients with psoriasis vulgaris were given 3.0mg/kg/day Neoral twice per day. We measured 4 points (C0 (base levels), C1 (1hr post dose), C2 (2hr post dose), andC4 (4hr post dose)) of pharmacokinetics during the 4 hours following administration of the drug and calculated AUC0-4 (area under concentration-time curve 0-4 hr). The relationships between AUC0-4 and C0, C1, C2, C4 were analyzed. There was a correlation between C2 and AUC0-4 (r=0.87, p<0.001). AUC0-4 correlations with clinical events during cyclosporine treatment were recognized in transplant recipient patients. These results suggest that C2 monitoring is important for determining CYA dosage based on the TDM for psoriasis.

Information related to the author
© 2002 Japanese Dermatological Association
Previous article Next article